Literature DB >> 31941754

AGO2 Mediates MYC mRNA Stability in Hepatocellular Carcinoma.

Kai Zhang1,2, Yotsawat Pomyen3,4, Anna E Barry1,2, Sean P Martin3, Subreen Khatib3, Lucy Knight3, Marshonna Forgues3, Dana A Dominguez3, Ravinder Parhar3, Ashesh P Shah1, Adam S Bodzin1, Xin Wei Wang5, Hien Dang6,2.   

Abstract

Deregulated RNA-binding proteins (RBP), such as Argonaute 2 (AGO2), mediate tumor-promoting transcriptomic changes during carcinogenesis, including hepatocellular carcinoma (HCC). While AGO2 is well characterized as a member of the RNA-induced silencing complex (RISC), which represses gene expression through miRNAs, its role as a bona fide RBP remains unclear. In this study, we investigated AGO2's role as an RBP that regulates the MYC transcript to promote HCC. Using mRNA and miRNA arrays from patients with HCC, we demonstrate that HCCs with elevated AGO2 levels are more likely to have the mRNA transcriptome deregulated and are associated with poor survival. Moreover, AGO2 overexpression stabilizes the MYC transcript independent of miRNAs. These observations provide a novel mechanism of gene regulation by AGO2 and provide further insights into the potential functions of AGO2 as an RBP in addition to RISC. IMPLICATIONS: Authors demonstrate that the RBP Argonaute 2 stabilizes the MYC transcript to promote HCC. ©2020 American Association for Cancer Research.

Entities:  

Year:  2020        PMID: 31941754      PMCID: PMC7127970          DOI: 10.1158/1541-7786.MCR-19-0805

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  39 in total

1.  Control of c-myc mRNA half-life in vitro by a protein capable of binding to a coding region stability determinant.

Authors:  P L Bernstein; D J Herrick; R D Prokipcak; J Ross
Journal:  Genes Dev       Date:  1992-04       Impact factor: 11.361

Review 2.  MicroRNA biogenesis and cancer.

Authors:  Richard I Gregory; Ramin Shiekhattar
Journal:  Cancer Res       Date:  2005-05-01       Impact factor: 12.701

3.  HuR recruits let-7/RISC to repress c-Myc expression.

Authors:  Hyeon Ho Kim; Yuki Kuwano; Subramanya Srikantan; Eun Kyung Lee; Jennifer L Martindale; Myriam Gorospe
Journal:  Genes Dev       Date:  2009-07-02       Impact factor: 11.361

Review 4.  MYC and the control of apoptosis.

Authors:  Steven B McMahon
Journal:  Cold Spring Harb Perspect Med       Date:  2014-07-01       Impact factor: 6.915

5.  Germline and somatic DICER1 mutations in familial and sporadic liver tumors.

Authors:  Stefano Caruso; Julien Calderaro; Eric Letouzé; Jean-Charles Nault; Gabrielle Couchy; Anaïs Boulai; Alain Luciani; Elie-Serge Zafrani; Paulette Bioulac-Sage; Olivier Seror; Sandrine Imbeaud; Jessica Zucman-Rossi
Journal:  J Hepatol       Date:  2016-12-22       Impact factor: 25.083

Review 6.  MYC on the path to cancer.

Authors:  Chi V Dang
Journal:  Cell       Date:  2012-03-30       Impact factor: 41.582

7.  RNA-binding protein PCBP2 modulates glioma growth by regulating FHL3.

Authors:  Wei Han; Zhongshuai Xin; Zhiqiang Zhao; Wen Bao; Xihua Lin; Bin Yin; Jizong Zhao; Jiangang Yuan; Boqin Qiang; Xiaozhong Peng
Journal:  J Clin Invest       Date:  2013-04-15       Impact factor: 14.808

8.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

9.  Identifying mRNA sequence elements for target recognition by human Argonaute proteins.

Authors:  Jingjing Li; TaeHyung Kim; Razvan Nutiu; Debashish Ray; Timothy R Hughes; Zhaolei Zhang
Journal:  Genome Res       Date:  2014-03-24       Impact factor: 9.043

10.  Three-dimensional Organotypic Culture Models of Human Hepatocellular Carcinoma.

Authors:  Atsushi Takai; Valerie Fako; Hien Dang; Marshonna Forgues; Zhipeng Yu; Anuradha Budhu; Xin Wei Wang
Journal:  Sci Rep       Date:  2016-02-16       Impact factor: 4.379

View more
  4 in total

Review 1.  Delivery of CRISPR-Cas9 system for screening and editing RNA binding proteins in cancer.

Authors:  Jingyue Yan; Diana D Kang; Gillian Turnbull; Yizhou Dong
Journal:  Adv Drug Deliv Rev       Date:  2021-11-09       Impact factor: 15.470

2.  The RNA-Binding Protein HuR Posttranscriptionally Regulates the Protumorigenic Activator YAP1 in Pancreatic Ductal Adenocarcinoma.

Authors:  Samantha Z Brown; Grace A McCarthy; James R Carroll; Roberto Di Niro; Carl Pelz; Aditi Jain; Thomas L Sutton; Hannah D Holly; Avinoam Nevler; Christopher W Schultz; Matthew D McCoy; Joseph A Cozzitorto; Wei Jiang; Charles J Yeo; Dan A Dixon; Rosalie C Sears; Jonathan R Brody
Journal:  Mol Cell Biol       Date:  2022-06-15       Impact factor: 5.069

3.  Establishment and validation of an RNA binding protein-associated prognostic model for ovarian cancer.

Authors:  Chaofan He; Fuxin Huang; Kejia Zhang; Jun Wei; Ke Hu; Meng Liang
Journal:  J Ovarian Res       Date:  2021-02-07       Impact factor: 4.234

4.  Systematic Construction and Validation of an RNA-Binding Protein-Associated Model for Prognosis Prediction in Hepatocellular Carcinoma.

Authors:  Siyuan Tian; Jingyi Liu; Keshuai Sun; Yansheng Liu; Jiahao Yu; Shuoyi Ma; Miao Zhang; Gui Jia; Xia Zhou; Yulong Shang; Ying Han
Journal:  Front Oncol       Date:  2021-01-26       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.